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Abstract
Background. Underuse of thromboprophylaxis in hospitalized medical patients is still common worldwide. 
Little is known about the use of thromboprophylaxis in patients with pulmonary diseases in everyday hospital 
practice.
Objectives. The aim of this study was to assess the use of pharmacological prophylaxis of venous throm-
boembolism (VTE) in real-life patients with pulmonary diseases.
Material and methods. In this retrospective study, 2 validated scoring systems, i.e., the Padua predic-
tion score and Caprini VTE risk assessment, were used to assess the VTE risk in 2011 patients (1133 men and 
878 women), aged 18 years or more, hospitalized for pulmonary diseases (median 6 days) in a single tertiary 
pulmonary medical center from January to December 2014.
Results. Using the Padua prediction score, we identified 428 (21.28%) patients at a high risk for VTE, includ-
ing 167 (39.01%) who received thromboprophylaxis with low-molecular-weight heparin, and 261 (60.98%) 
individuals at a high risk without thromboprophylaxis (p < 0.001). A total of 888 (44.16%) patients who 
scored 5 points or more using the Caprini VTE risk assessment were identified as subjects at a high risk for 
VTE, including 34.79% of patients receiving thromboprophylaxis. From among patients at a high risk for VTE, 
579 (65.20%) did not receive appropriate thromboprophylaxis (p < 0.001). Underuse of thromboprophylaxis 
was observed more commonly among patients hospitalized for lung cancer or pneumonia (50.60% and 
24.87% of patients at a high risk for VTE without prophylaxis, respectively).
Conclusions. Thromboprophylaxis is underutilized in hospitalized patients with pulmonary diseases re-
gardless of the scoring system used. Implementation of thromboprophylaxis should be markedly improved 
in this patient group.
Key words: venous thromboembolism, thromboprophylaxis, pulmonary diseases, Padua prediction score, 
Caprini VTE risk assessment
Original papers
Real-life use of thromboprophylaxis  
in patients hospitalized for pulmonary disorders: 
A single-center retrospective study
Robert F. Łukaszuk1, A–D, F, Krzysztof Plens2, C, F, Anetta Undas3, 4, A, C, E, F
1 Pulmonology Ward, The John Paul II Hospital, Kraków, Poland
2 Krakow Cardiovascular Research Institute (KCRI), Poland
3 Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
4 Krakow Centre for Medical Research and Technologies, The John Paul II Hospital, Kraków, Poland
A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; 
D – writing the article; E – critical revision of the article; F – final approval of the article
Advances in Clinical and Experimental Medicine, ISSN 1899–5276 (print), ISSN 2451–2680 (online) Adv Clin Exp Med. 2018;27(2):237–243
R. Łukaszuk, K. Plens, A. Undas. Use of thromboprophylaxis in pulmonology238
Introduction
Hospitalization is associated with an increased risk 
of developing venous thromboembolism (VTE) and leads 
to 10–20% of the VTE episodes in the general popula-
tion.1–3 Importantly, 10% of in-hospital deaths are related 
to VTE.4–6 It has been estimated that 42% of hospitalized 
patients are at an intermediate or high risk for VTE.1 An in-
creased risk of VTE is also observed during the 30-day 
post-discharge period.1,7
Appropriate pharmacologic prophylaxis to prevent VTE 
with its consequences has been recognized as a key medi-
cal intervention among patients admitted to hospital, as it 
directly increases their safety, reduces the occurrence of 
VTE, and reduces the cost of medical treatment. Appropri-
ate thromboprophylaxis reduces the risk of VTE by half.8,9 
Surgical patients benefit more than medical patients. 
The 2012 and 2016 guidelines of the American College of 
Chest Physicians (ACCP) strongly recommend pharmaco-
logic prophylaxis among hospitalized patients at a high risk 
for VTE (grade 1B), or mechanical thromboprophylaxis in 
patients at a high risk for VTE as well as for bleeding, or 
those who bleed actively (grade 2C).9,10 Identification of 
high-risk VTE patients who should receive thrombopro-
phylaxis during the hospital stay can be done by means of 
validated scoring systems, which usually divide patients 
into high and low risk groups. The former group should 
receive thromboprophylaxis. The ACCP recommends the 
Padua prediction score,11 a validated risk assessment model 
identifying patients at a high risk for VTE (4 points or 
more) and those at a low risk for VTE (fewer than 4 points). 
There is an alternative to the Padua prediction score, the 
Caprini VTE risk assessment, in which a high risk for VTE 
is defined as 5 points or more. It is important to consis-
tently use 1 system in everyday hospital practice. The rec-
ommended thromboprophylaxis during hospitalization is 
heparin, most common worldwide, low-molecular-weight 
heparin (LMWH) s.c., or, infrequently, unfractionated hep-
arin (UFH), or, very rarely, fondaparinux.9,10 Neither the 
use of aspirin nor the use of antiplatelet agents is recom-
mended as a prophylaxis of VTE.9,10 The effectiveness of 
thromboprophylaxis was assessed in 3 large clinical trials, 
namely MEDENOX (the Medical Patients with Enoxaparin 
Trial), in which enoxaparin was used once daily;12 PRE-
VENT (the Prospective Evaluation of Dalteparin Efficacy 
for Prevention of VTE in Immobilized Patients Trial), in 
which dalteparin was used once daily;13 and ARTEMIS 
(the Affordability and Real-World Antiplatelet Treatment 
Effectiveness After Myocardial Infarction Study), in which 
fondaparinux was used once daily.14 Some newer oral anti-
coagulants, e.g., apixaban, dabigatran, and rivaroxaban, can 
be used as thromboprophylaxis after hospitalization due to 
surgical indications solely in orthopedic patients.9,10 The op-
timal duration of VTE prophylaxis in medical patients is 
unknown. The current approach is to use it during the whole 
hospitalization period, and under some circumstances 
it might be continued for 28 days after discharge.9,10
Physicians who refer medical patients to hospital and 
then take care of them may still fail to put them on throm-
boprophylaxis in accordance with the ACCP guidelines. 
They commonly perceive some patients as low-risk individ-
uals, especially if the planned hospital stay is short. On the 
other hand, there is a subset of patients with a low or mod-
erate risk for VTE who receive pharmacologic thrombo-
prophylaxis during hospital stay, which increases the risk 
of bleeding, and cost.
A particular group of medically-treated patients who 
often require thromboprophylaxis during hospitalization 
are patients with pulmonary disease. For example, the risk 
of VTE in chronic obstructive pulmonary disease (COPD) 
exacerbation ranges from 5% to even 29%.15–18 Postmortem 
examination of patients who died due to COPD exacer-
bation have demonstrated pulmonary embolism (PE) in 
28–51% of cases.19,20 Lung cancer is a well- established 
potent risk factor for developing VTE.21–25 Respiratory 
diseases of low prevalence are reported to be associated 
with an elevated VTE risk. The risk of VTE in patients with 
pulmonary fibrosis has been estimated as 34% higher than 
in the background population, and 44% and 54% greater 
than among patients with COPD and lung cancer, respec-
tively.26 Asthma is also increasingly perceived as a disease 
related to an increased VTE risk.27
The Epidemiologic International Day for the Evalua-
tion of Patients at Risk for Venous Thromboembolism in 
the Acute Hospital Care Setting (ENDORSE) study was 
also performed in Poland and its results were published 
in 2007.28,29 It was found that as few as 51.8% of high-risk 
patients received the thromboprophylaxis recommend-
ed by the ACCP (54.7% of surgical patients and 32.5% 
of nonsurgical patients). In this study, pulmonary patients 
constituted 26.8% of all evaluated subjects. The  main 
cause of hospitalization was pneumonia (17.6%) and acute 
respiratory infections (9.2%).29 Recently, the proportion 
of hospitalized, medically-treated patients with pulmo-
nary disorders has been increasing in the aging popula-
tions; however, PE still remains the main preventable cause 
of death in this population.4–6
Objectives
To our knowledge, there have been no published reports 
on VTE risk in real-life patients hospitalized in pulmonology 
wards in recent years. Therefore, the aim of our study was to 
evaluate the risk of  VTE among hospitalized patients and 
the use of thromboprophylaxis in a ward in which patients 
with respiratory disorders are treated. We sought to as-
sess the current trends in thromboprophylaxis in patients 
hospitalized for pulmonary diseases in tertiary specialist 
hospitals.
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Material and methods
In this retrospective study, we enrolled all the patients aged 
18 years or more, hospitalized from January 1, 2014 to De-
cember 31, 2014 in the Pulmonology Ward of the John Paul II 
Hospital in Krakow, Poland. Solely patients who stayed in the 
hospital for more than 24 h were eligible. The hospitalized 
patients did not need intensive care. No exclusion criteria 
were used for patients admitted to the ward. The study was 
carried out in accordance with local legal regulations.
All patients were classified into one of 6 core groups 
based on the main cause of hospitalization identified at 
discharge.
Medical data, i.e., demographics, basic and concomitant 
diseases, duration of hospitalization, and medications, was 
collected on the basis of hospital records. Patients’ physical 
activity when hospitalized, reduced mobility making a pa-
tient stay in bed for more than 30 min during 3 consecutive 
days as well as any non-pharmacologic thromboprophy-
laxis were determined on the basis of nursing care records.
We selected 2 validated scoring systems, the Padua pre-
diction score and Caprini VTE risk assessment, and evalu-
ated the VTE risk in all patients.9,11 2014 was the last year 
prior to the implementation of 1 recommended VTE risk 
assessment tool for the patients hospitalized in the ward.
The  Padua prediction score was one model used to 
identify patients at a high risk for VTE when hospital-
ized. The group included patients whose score was 4 or 
higher. Those whose score was lower than 4 were identified 
as at a low risk for VTE when hospitalized. The Caprini 
VTE risk assessment was the other model used to identify 
patients at a high risk for VTE when hospitalized. Those 
whose score was 4 or lower were identified as not at a high 
risk for VTE when hospitalized. The group included those 
whose score was 5 or higher.
Administration of enoxaparin (40 mg once daily from 
the first to the last day of hospitalization) was used as 
thromboprophylaxis for all patients at a high risk for VTE. 
Mechanical thromboprophylaxis was not used.
Not using thromboprophylaxis in patients at a high risk for 
VTE was recognized as the underuse of prophylaxis, while the 
overuse of prophylaxis was recognized as using any throm-
boprophylaxis in patients identified as at a low risk for VTE.
Statistical analysis
The variables were presented as number and percentage. 
Categorical variables in the subgroups were compared by 
the Pearson’s χ2 test or the Fisher’s exact test for 2 × 2 tables. 
All p-values presented were two-sided and were considered 
as statistically significant if below 0.05. All calculations 
were done with JMP® v. 12.2.0 (SAS Institute Inc., Cary, 
USA). The Caprini VTE risk assessment and Padua pre-
diction score were expressed as median and interquartile 
range (IQR), and were compared with the Mann-Whitney 
U test and the Kruskal-Wallis test.
Results
A total of 2011 individuals aged between 18 and 94 (me-
dian: 66) years, including 1133 (56.4%) men and 878 (45.6%) 
women, were analyzed (Table  1). The  mean duration 
of hospitalization was 6 days. The most common causes 
of hospitalization were pneumonia (n = 780; 38.8%) and 
lung cancer (n = 551; 27.4%). Eighty-seven (4.3%) patients 
were on anticoagulation with vitamin K  antagonists 
(VKAs) on admission. During hospitalization, 368 (18.3%) 
patients received thromboprophylaxis with enoxaparin.
Padua prediction score
Using the Padua prediction score, we identified 428 
(21.28%) patients at a high risk for VTE, including 167 
(39.01%) who received thromboprophylaxis. As many as 
60.98% of high-risk patients did not receive thrombopro-
phylaxis (Table 2). Out of the 1583 (78.7%) patients with 
a low risk of VTE, 201 (9.99%) received thromboprophy-
laxis (p < 0.001) (Table 2).
Caprini VTE risk assessment
A total of 888 (44.16%) patients scored 5 points or more 
using the Caprini VTE risk assessment, and were identified 
as subjects at a high risk for VTE, including 309 (34.79%) 
who received thromboprophylaxis. On the other hand, 
579 (65.20%) individuals who were at a high risk for VTE 
did not receive appropriate thromboprophylaxis (Table 3). 
The number of patients identified as at a low risk for VTE 
was 1123 (55.88%). Fifty-nine of them received thrombo-
prophylaxis despite having no indications, which makes 
up 5.25% of the cohort (p < 0.001) (Table 3).
The main cause of hospitalization
The main causes of hospitalization among patients re-
quiring thromboprophylaxis were diseases of airways, lung 
cancer, interstitial lung disease, pneumonia, and respira-
tory failure. A total of 138 (15.54%) patients with diseases 
of airways scored 5 points or more using the Caprini VTE 
risk assessment, and were identified as at a high risk of 
VTE. Ninety (15.54%) individuals were identified as un-
derusing thromboprophylaxis (Table 3). Using the Padua 
prediction score with this group, 12 (4.60%) patients were 
demonstrated to underuse thromboprophylaxis (Table 2).
Among lung cancer patients, 293 (50.60%) individuals were 
identified as underusing thromboprophylaxis according 
to the Caprini VTE risk assessment (Table 3). Using the Pad-
ua prediction score in this group, 218 (83.52%) patients were 
demonstrated to underuse thromboprophylaxis (Table 2).
According to the Caprini VTE risk assessment, 
38 (6.56%) of the interstitial lung disease patients were also 
underusing thromboprophylaxis (Table 3). Using the Padua 
prediction score with these patients, 3 (1.15%) individuals 
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were in the same group of patients underusing thrombo-
prophylaxis (Table 2).
Underuse of thromboprophylaxis in hospitalized pa-
tients was also observed in patients with pneumonia. 
As many as 203 (22.86%) of them scored 5 points or more 
using the Caprini VTE risk assessment, and were iden-
tified as at a high risk for VTE. A total of 144 (24.87%) 
individuals were identified to underuse thrombopro-
phylaxis (Table  3). Using the Padua prediction score, 
27 (10.34%) patients were demonstrated to underuse 
thromboprophylaxis (Table 2).
Among respiratory failure patients, as few as 10 (1.73%) 
individuals were identified to underuse thromboprophylax-
is according to the Caprini VTE risk assessment (Table 3). 
Using the Padua prediction score, none of them was dem-
onstrated to underuse thromboprophylaxis (Table 2).
Using the Padua prediction score, the overuse of throm-
boprophylaxis was common in the following groups based 
Table 1. Characteristics of the study cohort
Characteristics
The whole 
population 
n = 2011
Patients who received 
thromboprophylaxis 
n = 368 (18.3%)
Patients who did not receive 
thromboprophylaxis 
n = 1643 (81.7%)
p-value
Age > 70 years 632 (31.4) 177 (8.8) 455 (22.6) <0.001
Men 1133 (56.4) 213 (10.6) 920 (45.7) 0.52
BMI > 30 kg/m2 349 (17.3) 77 (3.8) 272 (13.5) 0.05
Acute patients 124 (6.2) 13 (0.6) 111 (5.5) 0.02
Elective patients 1887 (93.8) 355 (17.6) 1532 (76.2) 0.02
Cause of hospitalization 
Airways diseases1 332 (16.5) 65 (3.2) 267 (13.3) <0.001
Interstitial lung disease2 268 (13.3) 11 (0.5) 257 (12.8) <0.001
Lung cancer 551 (27.4) 160 (7.9) 391 (19.4) <0.001
Pneumonia 780 (38.8) 77 (10.5) 703 (34.9) <0.001
Pulmonary embolism 52 (2.6) 46 (2.3) 6 (0.3) <0.001
Respiratory failure 28 (1.4) 9 (0.4) 19 (0.9) <0.001
Comorbidities 
Arrhythmia 79 (3.9) 63 (3.1) 16 (0.8) <0.001
Diabetes 127 (6.3) 27 (1.3) 100 (5.0) 0.41
Arterial hypertension 859 (42.7) 215 (10.7) 644 (32.0) <0.001
Heart failure 14 (0.7) 10 (0.5) 4 (0.2) <0.001
Thyroid disorders 35 (1.7) 3 (0.1) 32 (1.6) 0.18
Previous venous thromboembolism 13 (0.6) 9 (0.4) 4 (0.1) <0.001
Varicose veins 164 (8.2) 68 (3.4) 96 (4.8) <0.001
Other diseases 44 (2.2) 20 (1.0) 24 (1.2) <0.001
Medications on admission
Oral corticosteroids 27 (1.3) 12 (0.6) 15 (0.7) 0.01
VKA  87 (4.3) 67 (3.3) 20 (1.0) <0.001
Risk scores
Padua prediction score low risk
(<4 points)
1583 (78.7) 201 (10.0) 1382 (68.7) <0.001
Padua prediction score high risk
(≥4 points)
428 (21.3) 167 (8.3) 261 (13.0) <0.001
Caprini VTE risk assessment score low risk
(1–2 points)
322 (16.3) 7 (0.3) 315 (16.0) <0.001
Caprini VTE risk assessment score medium risk
(3–4 points)
795 (39.5) 52 (2.6) 743 (36.9) <0.001
Caprini VTE risk assessment score high risk
(≥5 points)
888 (44.2) 299 (15.4) 589 (28.8) <0.001
Death 7 (0.3) 2 (0.1) 5 (0.2) 0.62
Data was shown as number (percentage). VKA – oral anticoagulant therapy; BMI – body mass index; 1 asthma, chronic obstructive pulmonary disease and 
bronchiectasis; 2 idiopathic pulmonary fibrosis, sarcoidosis, nonspecific interstitial pneumonia, and hypersensitivity pneumonitis.
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on the main causes of hospitalization: diseases of airways 
(n = 63; 31.34%); pneumonia (n = 63; 31.34%); and pulmo-
nary embolism (n = 36; 17.91%) (Table 2). Using the Caprini 
VTE risk assessment, the overuse of thromboprophylaxis 
was common in patients with diseases of airways (n = 17; 
28.81%), pulmonary embolism (n = 15; 25.42%), and pneu-
monia (n = 18; 30.51%) (Table 3).
Underuse of thromboprophylaxis was identified in some 
components of the Padua prediction score: active cancer 
(99.23%); acute infection or rheumatic disease (83.52%); 
and advanced age (40.61%) (Table 2). Taking into account 
the components of the Caprini VTE risk assessment and 
underuse of thromboprophylaxis, we observed among the 
patient groups: abnormal pulmonary function (99.65%); se-
rious lung diseases (75.24%); and BMI > 25 kg/m2 (63.73%) 
(Table 3).
Discussion
To  our knowledge, this study is the largest analysis 
of the current everyday practice in thromboprophylaxis 
in patients hospitalized for pulmonary diseases. Given 
the rising prevalence of several pulmonary diseases in the 
general population, e.g., COPD, the significant risk for VTE 
during a hospital stay should also be acknowledged in this 
subset of medical patients. The current guidelines make it 
possible to choose 1 of a few validated scoring system to 
evaluate the VTE risk; however, using 2 of the tested scores, 
namely the Padua prediction score and Caprini VTE risk 
assessment, the proportion of patients with pulmonary dis-
ease who are deprived of benefits from the prophylactic use 
of LMWH is substantial. This observation indicates that 
every patient hospitalized for medical reasons should be 
assessed as a potential candidate for thromboprophylaxis.
There was a large subset of patients with pulmonary dis-
eases hospitalized, i.e., 60.98% according to the Padua pre-
diction score and 65.20% according to the Caprini VTE risk 
assessment, who did not receive proper prophylaxis of VTE. 
A much lower proportion of patients hospitalized for pul-
monary disorders, i.e., 9.99% based on the Padua prediction 
score and 5.25% based on the Caprini VTE risk assessment, 
received prophylaxis of VTE, but did not need it according 
to the current recommendations. Compared to the 2007 
ENDORSE study, the proportion of pulmonary patients 
without thromboprophylaxis during a hospital stay is 
comparable to the data obtained in non-surgical wards.29 Our 
findings highlight the need for widespread use of thrombo-
prophylaxis in medical patients, including those from pulmo-
nary wards. The proportion of patients on thromboprophy-
laxis during a hospital stay is still suboptimal, and without 
significant improvement after about 10 years.
We  identified some subsets of patients with pul-
monary disorders who are more likely not to receive 
Table 2. Use of thromboprophylaxis according to Padua prediction score
Variable
Patients who 
should receive 
thrombo prophylaxis 
according to Padua 
prediction score
≥ 4 points
Patients who 
should not receive 
thrombo prophylaxis 
according to Padua 
prediction score
< 4 points
Patients 
who 
received 
thrombo-
prophylaxis
Patients who 
did not receive 
thrombo-
prophylaxis 
despite 
indication
Patients who 
received 
thrombo-
prophylaxis 
without 
indication
p-value
Padua prediction score
≥ 4 points
428 (21.28) 1583 (78.7) 167 (39.01) 261 (60.98) 201 (9.99) <0.001
Main cause of hospitalization
Airways diseases1 14 (3.27) 318 (20.09) 2 (13.17) 12 (4.60) 63 (31.34) <0.001
Lung cancer 359 (83.88) 192 (50.03) 141 (84.43) 218 (83.52) 19 (9.45) <0.001
Interstitial lung disease 3 (0.70) 265 (16.74) 0 (0.00) 3 (1.15) 11 (5.47) 0.0006
Respiratory failure 0 (0.00) 28 (1.77) 0 (0.00) 0 (0.00) 9 (4.48) <0.001
Pneumonia 41 (9.58) 739 (46.68) 14 (8.38) 27 (10.34) 63 (31.34) <0.001
Pulmonary embolism 11 (2.57) 41 (2.59) 10 (5.99) 1 (0.38) 36 (17.91) <0.001
Components of Padua prediction score
Active cancer 419 (97.89) 68 (4.29) 160 (95.81) 259 (99.23) 7 (3.48) <0.001
Previous VTE 9 (2.10) 4 (0.25) 7 (4.19) 2 (0.77) 1 (0.50) 0.0071
Advanced age (>70 years) 173 (40.42) 459 (29.00) 67 (40.12) 106 (40.61) 110 (54.73) 0.0035
Heart or respiratory failure 5 (1.17) 9 (0.57) 5 (2.99) 0 (0.0) 5 (2.49) 0.0253
Acute infection and/or rheumatic disease 367 (85.75) 599 (37.84) 149 (89.22) 218 (83.52) 140 (69.65) <0.001
BMI > 30 kg/m2 75 (17.52) 274 (17.31) 36 (21.56) 39 (14.94) 41 (20.40) 0.1562
Hormonal treatment 17 (3.97) 10 (0.63) 10 (5.99) 7 (2.68) 2 (0.99) 0.0189
Thrombophilia 1 (0.23) 1 (0.06) 1 (0.60) 0 (0.00) 1 (0.05) 0.4837
1 Asthma, chronic obstructive pulmonary disease and bronchiectasis.
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thromboprophylaxis during a hospital stay. It is disturb-
ing to demonstrate that more than 50% of lung cancer 
patients did not receive thromboprophylaxis despite clear 
indications. Approximately 3% of lung cancer patients de-
velop VTE within 2 years of diagnosis and this complica-
tion is associated with a 50% higher risk of death within 
2 years.23,24 These findings strongly support the need for 
much more common use of thromboprophylaxis in cancer 
patients.
The issue of prophylaxis in pulmonary embolism (PE) 
patients deserves a comment. Most of patients with PE, 
including incidental pulmonary embolism, received throm-
boprophylaxis in spite of being at a low risk for VTE (36 pa-
tients at a low risk for VTE according to the Padua predic-
tion score, and 15 individuals according to the Caprini VTE 
risk assessment). It seems that this observation results 
from better implementation of the recommendations for 
PE treatment in the pulmonary ward. Obviously, patients 
with confirmed PE were treated, as recommended, mostly 
with therapeutic doses of LMWH during the hospital 
stay.
This study has several limitations. The study is ret-
rospective, which implies some problems with data 
acquisition and their precision. We did not have data from 
other years to compare the trends in thromboprophylaxis 
in our hospital. In some patients, the diagnosis could have 
been not convincingly established and, for example, we 
could not address the issue as to whether asthma was as-
sociated with a comparable risk of VTE vs COPD. We did 
not assess the impact of certain comorbidities and high-
risk VTE factors, e.g., recent myocardial infraction, stroke, 
injury or surgery, since none of the enrolled patients ex-
perienced such disease states. An analysis of the clinical 
outcomes of under- or overuse of thromboprophylaxis 
during a hospital stay and follow-up was beyond the scope 
of the current study.
From the practical point of view, it is important to put 
more focus on a proper assessment of patients at a high 
risk for VTE, and consistently use 1 assessment model to 
identify patients at a high risk for VTE. We believe that 
since at the John Paul II Hospital the Caprini VTE risk 
assessment was implemented as a preferred tool for as-
sessing the patients’ risk of VTE during hospitalization, the 
proportion of patients who can benefit from LMWH has 
been improving, also leading to better clinical outcomes 
among patients treated for pulmonary diseases.
Table 3. Use of thromboprophylaxis according to Caprini VTE risk assessment
Variable
Patients who should 
receive thrombo-
prophylaxis according 
to Caprini VTE risk 
assessment
≥ 5 points
Patients who should 
not receive thrombo-
prophylaxis according 
to Caprini VTE risk 
assessment
< 5 points
Patients who 
received 
thrombo-
prophylaxis
Patients who 
did not receive 
thrombo-
prophylaxis 
despite indication
Patients who 
received 
thrombo-
prophylaxis 
without 
indication
p-value
Caprini VTE risk assessment
≥ 5 points
888 (44.16) 1123 (55.88) 309 (34.79) 579 (65.20) 59 (5.25) <0.001
Main cause of hospitalization
Airways diseases1 138 (15.54) 194 (17.27) 48 (15.53) 90 (15.54) 17 (28.81) 0.028
Lung cancer 449 (50.56) 102 (9.08) 156 (50.48) 293 (50.60) 4 (6.78) <0.001
Interstitial lung disease 47 (5.29) 221 (19.68) 9 (2.91) 38 (6.56) 2 (3.39) 0.052
Respiratory failure 16 (1.80) 12 (1.07) 6 (1.94) 10 (1.73) 3 (5.08) 0.214
Pneumonia 203 (22.86) 577 (51.38) 59 (19.09) 144 (24.87) 18 (30.51) 0.061
Pulmonary embolism 35 (39.77) 17 (1.51) 31 (10.03) 4 (0.69) 15 (25.42) <0.001
Components of Caprini VTE risk assessment
Age 41–60 years 93 (10.47) 396 (35.26) 28 (9.06) 65 (11.23) 18 (30.51) <0.001
Age 61–75 years 431 (48.53) 434 (38.65) 146 (47.25) 285 (49.22) 27 (45.76) 0.7848
Age > 75 years 357 (40.20) 50 (4.45) 127 (41.10) 230 (39.72) 2 (3.39) <0.001
History of VTE 10 (1.13) 1 (0.09) 8 (2.59) 2 (0.35) 0 (0.00) 0.0056
Varicose veins 127 (14.30) 37 (3.29) 61 (19.74) 66 (11.40) 7 (11.86) 0.0027
Congestive heart failure 12 (1.35) 2 (0.18) 10 (3.24) 2 (0.35) 0 (0.00) 0.0008
Swollen legs 76 (8.56) 17 (1.51) 64 (20.71) 12 (2.07) 7 (11.86) <0.001
Serious lung diseases 682 (76.80) 299 (26.62) 262 (84.79) 420 (72.54) 32 (54.24) <0.001
Abnormal pulmonary function 885 (99.66) 1078 (95.99) 308 (99.68) 577 (99.65) 59 (100.00) 0.9035
Cancer 475 (51.46) 12 (1.07) 166 (53.72) 309 (53.37) 1 (1.69) <0.001
Thrombophilia 2 (0.22) 0 (0.00) 2 (0.65) 0 (0.00) 0 (0.00) 0.1263
BMI > 25 kg/m2 587 (66.10) 478 (42.56) 218 (70.55) 369 (63.73) 20 (33.90) <0.001
1 Asthma, chronic obstructive pulmonary disease and bronchiectasis.
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